Teva and Sanofi jump on experimental bowel disease drug success
In This Article:
Teva Pharmaceutical Industries (TEVA) and Sanofi (SNY) rise after the trial for their experimental inflammatory bowel disease drug showed promising results. Teva shares gain more than 25% during Tuesday's session, contributing to the stock more than doubling year-to-date.
Julie Hyman and Josh Lipton take a closer look at the pharmaceutical companies' stock moves and break down what investors need to know.
To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
This post was written by Naomi Buchanan.
Related Videos
Terms and Privacy Policy